Rioprostil: a clinical experience in gastric ulcer treatment.

Abstract

The efficacy and tolerability of the prostaglandin E1 derivative rioprostil (Bay o 6893) was studied in a randomized, double-blind, placebo-controlled trial in 40 patients affected by acute gastric ulcer. At the end of the eight weeks period ulcer healing was achieved in 85% of the rioprostil-treated patients and in 60% of the placebo-treated ones (p less than 0.05). Rioprostil produced a significant reduction of pain and also improved the clinical status. This positive outcome was noted both in smokers and in non-smoking patients, while only this last group improved during the placebo treatment.

• Authors: G Mascio, L Guida, M V Mascio, F Maggiolo
• Journal: International journal of clinical pharmacology research (Int J Clin Pharmacol Res) Vol. 8 Issue 5 Pg. 341-4 ( 1988) ISSN: 0251-1649 [Print] Switzerland
• PMID: 3147950 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)

Chemical References

• Prostaglandins E
• Rioprostil

Topics

• Administration, Oral
• Adult
• Clinical Trials as Topic
• Double-Blind Method
• Drug Administration Schedule
• Female
• Humans
• Male
• Middle Aged
• Prostaglandins E (administration & dosage, therapeutic use)
• Random Allocation
• Rioprostil
• Stomach Ulcer (drug therapy)